Kyverna Therapeutics, Inc. Statistics
Want to see KYTX full AI Analyst Report?
Kyverna Therapeutics, Inc. (KYTX) Stock Statistics & Valuation Metrics
Total Valuation
Kyverna Therapeutics, Inc. has a market cap or net worth of $319.27M. The enterprise value is $283.21M.
- Market Cap
- $319.27M
- Enterprise Value
- $283.21M
Share Statistics
Kyverna Therapeutics, Inc. has 63,221,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 63,221,970
- Owned by Insiders
- 22.84%
- Owned by Institutions
- 37.58%
Financial Efficiency
Kyverna Therapeutics, Inc.’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -64.99%.
- Return on Equity (ROE)
- -0.69
- Return on Assets (ROA)
- -0.55
- Return on Invested Capital (ROIC)
- -64.99%
- Return on Capital Employed (ROCE)
- -0.66
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.08M
- Employee Count
- 149
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Kyverna Therapeutics, Inc. is -1.82. Kyverna Therapeutics, Inc.’s PEG ratio is -0.06.
- PE Ratio
- -1.82
- PS Ratio
- 0.00
- PB Ratio
- 2.35
- Price to FCF
- -2.11
- Price to Operating Cash Flow
- -2.07
- PEG Ratio
- -0.06
Income Statement
In the last 12 months, Kyverna Therapeutics, Inc. had revenue of 0 and earned -161.31M in profits. Earnings per share was -3.64.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -169.83M
- Pretax Income
- -161.31M
- Net Income
- -161.31M
- EBITDA
- -159.02M
- Earnings Per Share (EPS)
- -3.64
Cash Flow
In the last 12 months, operating cash flow was -150.80M and capital expenditures -462,000, giving a free cash flow of -151.26M billion.
- Operating Cash Flow
- -150.80M
- Free Cash Flow
- -151.26M
- Free Cash Flow per Share
- -2.44
Dividends & Yields
Kyverna Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -47.38%
- Earnings Yield
- -50.43%
Stock Price Statistics
- Beta
- 1.90
- 52-Week Price Change
- -22.07%
- 50-Day Moving Average
- 6.28
- 200-Day Moving Average
- 7.91
- Relative Strength Index (RSI)
- 39.06
- Average Volume (3m)
- 864.35K
Important Dates
Kyverna Therapeutics, Inc. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Kyverna Therapeutics, Inc. as a current ratio of 7.75, with Debt / Equity ratio of 12.50%
- Current Ratio
- 7.75
- Quick Ratio
- 7.75
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 0.60
- Interest Coverage Ratio
- -347.29
Taxes
In the past 12 months, Kyverna Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Kyverna Therapeutics, Inc. EV to EBITDA ratio is -2.08, with an EV/FCF ratio of -2.11.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.08
- EV to Free Cash Flow
- -2.11
- EV to Operating Cash Flow
- -2.12
Balance Sheet
Kyverna Therapeutics, Inc. has $170.57M in cash and marketable securities with $32.45M in debt, giving a net cash position of $138.12M billion.
- Cash & Marketable Securities
- $170.57M
- Total Debt
- $32.45M
- Net Cash
- $138.12M
- Net Cash Per Share
- $2.18
- Tangible Book Value Per Share
- $2.15
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Kyverna Therapeutics, Inc. is $29.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $29.00
- Price Target Upside
- 474.26% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 25.69%
Scores
- Smart Score
- 5
- AI Score
- 47

